Dihydroergotamine

INDICATIONS AND USAGE

Dihydroergotamine Mesylate Injection is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.

Optimal results are obtained by titrating the dose for several headaches to find the minimal effective dose for each patient and this dose should then be employed at onset of subsequent attacks. M. administration and persists for 3 to 4 hours.

Repeated dosage at 1 hour intervals up to a total of 3 mL may be required to obtain maximal effect. The total weekly dosage should not exceed 6 mL (6 mg). V. route. Acute migraine attack: 1 mL (1 mg) by intramuscular or subcutaneous injection at the first sign of headache; in refractory cases, a further 1 mL may be administered after 30 to 60 minutes.

Do not exceed a total of 3 mL per attack or per day. 16 When more rapid effect is desired, the intravenous route may be employed: 1 mL (1 mg) by slow intravenous injection at the onset of the attack, followed in an hour by 1 mL (1 mg) if necessary.

Do not exceed a total of 2 mL (2 mg) per migraine attack. 5 mg) by slow intravenous injection. 8 Description: White or off-white, fine, crystalline, hygroscopic powder. Moderately soluble in water. s. 1 mL Storage requirements: Protect ampoules from light.

Treatment of acute attacks of migraine with or without aura